Microbial diversity in drug-naïve Parkinson's disease patients.
Parkinson's disease (PD) is a neurological disorder characterized by rigidity, bradykinesia and tremor. Several genetic and environmental causes of PD are known, and there is emerging evidence of the possible contribution of the gut microbiome to the disease onset, severity, and response to the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0328761 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849228057733234688 |
|---|---|
| author | Eliša Papić Valentino Rački Mario Hero Ana Nyasha Zimani Mojca Čižek Sajko Gloria Rožmarić Nada Starčević Čizmarević Saša Ostojić Miljenko Kapović Goran Hauser Aleš Maver Borut Peterlin Anja Kovanda Vladimira Vuletić |
| author_facet | Eliša Papić Valentino Rački Mario Hero Ana Nyasha Zimani Mojca Čižek Sajko Gloria Rožmarić Nada Starčević Čizmarević Saša Ostojić Miljenko Kapović Goran Hauser Aleš Maver Borut Peterlin Anja Kovanda Vladimira Vuletić |
| author_sort | Eliša Papić |
| collection | DOAJ |
| description | Parkinson's disease (PD) is a neurological disorder characterized by rigidity, bradykinesia and tremor. Several genetic and environmental causes of PD are known, and there is emerging evidence of the possible contribution of the gut microbiome to the disease onset, severity, and response to therapy. While previous research has shown several differences in the microbiome of PD patients under therapy as opposed to healthy controls, few prospective studies have included drug-naïve patients. In order to evaluate the gut microbiome composition prior to therapy initiation, we collected and performed 16S rRNA gene sequencing of the stool samples from 49 drug-naïve PD patients and compared them to 34 diet and lifestyle-matched controls from the Croatian population (GiOPARK Project). While no significant alpha diversity difference was observed between the patients and controls, the differential relative abundance analysis showed an increase in Bacteroides fluxus, B. interstinalis, B. eggerthii, and Dielma fastidiosa in the drug-naïve PD patients compared to controls, while Alistipes, Barnesiella and Dialister spp. were decreased in patients compared to controls. Despite preserved overall diversity, these changes may indicate early microbial dysbiosis and represent a foundation for future studies exploring microbiome changes across disease progression and treatment. |
| format | Article |
| id | doaj-art-071b4aa0e29f43a1a946144e8a5a888f |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-071b4aa0e29f43a1a946144e8a5a888f2025-08-23T05:32:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01208e032876110.1371/journal.pone.0328761Microbial diversity in drug-naïve Parkinson's disease patients.Eliša PapićValentino RačkiMario HeroAna Nyasha ZimaniMojca Čižek SajkoGloria RožmarićNada Starčević ČizmarevićSaša OstojićMiljenko KapovićGoran HauserAleš MaverBorut PeterlinAnja KovandaVladimira VuletićParkinson's disease (PD) is a neurological disorder characterized by rigidity, bradykinesia and tremor. Several genetic and environmental causes of PD are known, and there is emerging evidence of the possible contribution of the gut microbiome to the disease onset, severity, and response to therapy. While previous research has shown several differences in the microbiome of PD patients under therapy as opposed to healthy controls, few prospective studies have included drug-naïve patients. In order to evaluate the gut microbiome composition prior to therapy initiation, we collected and performed 16S rRNA gene sequencing of the stool samples from 49 drug-naïve PD patients and compared them to 34 diet and lifestyle-matched controls from the Croatian population (GiOPARK Project). While no significant alpha diversity difference was observed between the patients and controls, the differential relative abundance analysis showed an increase in Bacteroides fluxus, B. interstinalis, B. eggerthii, and Dielma fastidiosa in the drug-naïve PD patients compared to controls, while Alistipes, Barnesiella and Dialister spp. were decreased in patients compared to controls. Despite preserved overall diversity, these changes may indicate early microbial dysbiosis and represent a foundation for future studies exploring microbiome changes across disease progression and treatment.https://doi.org/10.1371/journal.pone.0328761 |
| spellingShingle | Eliša Papić Valentino Rački Mario Hero Ana Nyasha Zimani Mojca Čižek Sajko Gloria Rožmarić Nada Starčević Čizmarević Saša Ostojić Miljenko Kapović Goran Hauser Aleš Maver Borut Peterlin Anja Kovanda Vladimira Vuletić Microbial diversity in drug-naïve Parkinson's disease patients. PLoS ONE |
| title | Microbial diversity in drug-naïve Parkinson's disease patients. |
| title_full | Microbial diversity in drug-naïve Parkinson's disease patients. |
| title_fullStr | Microbial diversity in drug-naïve Parkinson's disease patients. |
| title_full_unstemmed | Microbial diversity in drug-naïve Parkinson's disease patients. |
| title_short | Microbial diversity in drug-naïve Parkinson's disease patients. |
| title_sort | microbial diversity in drug naive parkinson s disease patients |
| url | https://doi.org/10.1371/journal.pone.0328761 |
| work_keys_str_mv | AT elisapapic microbialdiversityindrugnaiveparkinsonsdiseasepatients AT valentinoracki microbialdiversityindrugnaiveparkinsonsdiseasepatients AT mariohero microbialdiversityindrugnaiveparkinsonsdiseasepatients AT ananyashazimani microbialdiversityindrugnaiveparkinsonsdiseasepatients AT mojcacizeksajko microbialdiversityindrugnaiveparkinsonsdiseasepatients AT gloriarozmaric microbialdiversityindrugnaiveparkinsonsdiseasepatients AT nadastarceviccizmarevic microbialdiversityindrugnaiveparkinsonsdiseasepatients AT sasaostojic microbialdiversityindrugnaiveparkinsonsdiseasepatients AT miljenkokapovic microbialdiversityindrugnaiveparkinsonsdiseasepatients AT goranhauser microbialdiversityindrugnaiveparkinsonsdiseasepatients AT alesmaver microbialdiversityindrugnaiveparkinsonsdiseasepatients AT borutpeterlin microbialdiversityindrugnaiveparkinsonsdiseasepatients AT anjakovanda microbialdiversityindrugnaiveparkinsonsdiseasepatients AT vladimiravuletic microbialdiversityindrugnaiveparkinsonsdiseasepatients |